#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Progressive supranuclear palsy


Authors: T. Bartošová 1;  J. Klempíř- 1 3
Authors place of work: Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze 1;  Anatomický ústav, 1. LF UK v Praze 2;  Evropská referenční síť pro vzácná neurologická onemocnění 3
Published in the journal: Cesk Slov Neurol N 2020; 83/116(6): 584-601
Category: Přehledný referát
doi: https://doi.org/10.48095/cccsnn2020584

Summary

Progressive supranuclear palsy is a tauopathy belonging to atypical Parkinsonian syndromes. The main clinical symptoms include oculomotor dysfunctions, early postural instability, symmetrical hypokinetic-rigid syndrome with axial predominance and cognitive decline. The symptom variability and rate of progression depend on disease subtype. Dia­gnostics are based on clinical symptoms; MRI remains the most useful auxiliary method. The article is focused mainly on clinical perspectives and recent dia­g­nostic approaches considering the latest recommendations. Symptomatic therapy remains of great importance as causal treatment is still lacking.

Keywords:

progressive supranuclear palsy – vertical gaze palsy – tauopathy – postural instability – parkinsonism – cognitive decline – Levodopa – amantadine


Zdroje

1. Ling H. Clinical approach to progressive supranuclear palsy. J Mov Disord 2016; 9 (1): 3–13. doi: 10.14802/jmd.15060.

2. Stamelou M, Giagkou N, Höglinger GU. One decade ago, one decade ahead in progressive supranuclear palsy. Mov Disord 2019; 34 (9): 1284–1293. doi: 10.1002/mds.27788.

3. McFarland, NR. Dia­gnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn) 2016; 22 (4 Movement Disorders): 1117–1142. doi: 10.1212/CON.0000000000000348.

4. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Mov Disord 2011; 26 (6): 1083–1095. doi: 10.1002/mds.23713.

5. Baba Y, Putzke JD, Whaley NR et al. Progressive supranuclear palsy: phenotypic sex differences in a clinical cohort. Mov Disord 2006; 21 (5): 689–692. doi: 10.1002/mds.20769.

6. Litvan I, Lees PS, Cunningham CR et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord 2016; 31 (5): 644–652. doi: 10.1002/mds.26512.

7. Steele JC, Capparos-Lefebvre D, Lees AJ et al. Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. Parkinsonism Relat Disord 2002; 9 (1): 39–54. doi: 10.1016/s1353-8020 (02) 00043-3.

8. Shoeibi A, Olfati N, Litvan I. Frontrunner in translation: progressive supranuclear palsy. Front Neurol 2019; 10: 1125. doi: 10.3389/fneur.2019.01125.

9. Mimuro M, Yoshida M. Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2020; 40 (1): 57–67. doi: 10.1111/neup.12590.

10. Fujita K, Matsubura T, Miyamoto R et al. Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report. BMC Neurol 2019; 19 (1): 168. doi: 10.1186/s12883-019-1402-7.

11. Ando S, Kanazawa M, Onodera O. Progressive supranuclear palsy with predominant cerebellar ataxia. J Mov Disord 2019; 13 (1): 20–26. doi: 10.14802/jmd.19061.

12. Vogels T, Leuzy A, Cicognola C et al. Propagation of tau pathology: integrating insights from postmortem and in vivo studies. Biol Psychiatry 2019; 87 (9): 808–818. doi: 10.1016/j.bio­psych.2019.09.019.

13. Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol 2017; 133 (5): 665–704. doi: 10.1007/s00401-017-1707-9.

14. Zhang CC, Xing A, Tan MS et al. The role of MAPT in neurodegenerative diseases: genetics, mechanisms and therapy. Mol Neurobio­l 2016; 53 (7): 4893–4904. doi: 10.1007/s12035-015-9415-8.

15. Huang Y, Wu Z, Zhou B. Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity. Cell Mol Life Sci 2016; 73 (1): 1–21. doi: 10.1007/s00018-015-2042-8.

16. Pérez MJ, Jara C, Quintanilla RA. Contribution of tau pathology to mitochondrial impairment in neurodegeneration. Front Neurosci 2018; 12: 441. doi: 10.3389/fnins.2018.00441.

17. Colin M, Dujardin S, Schraen-Maschke S et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 2020; 139 (1): 3–25. doi: 10.1007/s00401-019-02087-9.

18. Narasimhan S, Changolkar L, Riddle DM et al. Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. J Exp Med 2020; 217 (2): e20190783. doi: 10.1084/jem.20190783.

19. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick‘s disease. Brain Pathol 1999; 9 (4): 663–679. doi: 10.1111/j.1750-3639.1999.tb00549.x.

20. Ling H, De Silva R, Massey LA et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobio­l 2014; 40 (2): 149–163. doi: 10.1111/nan.12037.

21. Sakurai K, Tokumaru AM, Shimoji K et al. Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology 2017; 59 (5): 431–443. doi: 10.1007/s00234-017-1812-4.

22. Oyanagi K, Tsuchiya K, Yamazaki M et al. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. J Neuropathol Exp Neurol 2001; 60 (4): 393–402. doi: 10.1093/jnen/60.4.393.

23. MacLaren DA, Ljungberg TL, Griffin ME et al. Pedunculopontine tegmentum cholinergic loss leads to a progressive decline in motor abilities and neuropathological changes resembling progressive supranuclear palsy. Eur J Neurosci 2018; 48 (12): 3477–3497. doi: 10.1111/ejn.14212.

24. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994; 42: 229–246. doi: 10.1007/978-3-7091-6641-3_18.

25. Respondek G, Kurz C, Arzberger T et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017; 32 (7): 995–1005. doi: 10.1002/mds.27034.

26. Schirinzi T, Sancesario GM, Di Lazzaro G et al. Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm (Vienna) 2018; 125 (9): 1373–1379. doi: 10.1007/s00702-018-1893-1.

27. Wang SY, Chen W, Xu W et al. Neurofilament light chain in cerebrospinal fluid and blood as a bio­marker for neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimers Dis 2019; 72 (4): 1353–1361. doi: 10.3233/JAD-190615.

28. Donker Kaat L, Meeter LH, Zheng Chiu W et al. Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 2018; 56: 98–101. doi: 10.1016/j.parkreldis.2018.06.018.

29. Kataoka H, Sugie K. Serum adiponectin levels between patients with Parkinson‘s disease and those with PSP. Neurol Sci 2020; 41 (5): 1125–1131. doi: 10.1007/s10072-019-04216-4.

30. Eraslan C, Acaer A, Guneyli S et al. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson‘s disease and multiple system atrophy. Neurol Res 2019; 41 (2): 110–117. doi: 10.1080/01616412.2018.1541115.

31. Mueller C, Hussl A, Krismer F et al. The dia­gnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018; 54: 90–94. doi: 10.1016/j.parkreldis.2018.04.005.

32. Mostile G, Nicoletti A, Cicero CE et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurol Sci 2016; 37 (4): 591–595. doi: 10.1007/s10072-016-2489-x.

33. Quattrone A, Morelli M, Nigro S et al. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson‘s disease. Parkinsonism Relat Disord, 2018. 54: 3–8. doi: 10.1016/j.parkreldis.2018.07.016.

34. Constantinides VC, Paraskevas GP, Stamboulis E et al. Simple linear brainstem MRI measurements in the differential dia­gnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy. Neurol Sci 2018; 39 (2): 359–364. doi: 10.1007/s10072-017-3212-2.

35. Quattrone A, Morelli M, Quattrone A et al. Magnetic resonance parkinsonism index for evaluating disease progression rate in progressive supranuclear palsy: a longitudinal 2-year study. Parkinsonism Relat Disord 2020; 72: 1–6. doi: 10.1016/j.parkreldis.2020.01.019.

36. Oktay C, Özkaynak SS, Eseroğlu E et al. Contribution of the mesencephalon indices to differential dia­gnosis of parkinsonian disorders. Can Assoc Radiol J 2020; 71 (1): 100–109. doi: 10.1177/0846537119888411.

37. Mitchell T, Archer DB, Chu WT et al. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in parkinsonism. Hum Brain Mapp 2019; 40 (17): 5094–5107. doi: 10.1002/hbm.24760.

38. Richter D, Katsanos AH, Schroeder C et al. Lentiform nucleus hyperechogenicity in parkinsonian syndromes: a systematic review and meta-analysis with consideration of molecular pathology. Cells 2019; 9 (1): 2. doi: 10.3390/cells9010002.

39. Alonso-Canovas A, Ferrairó JI, Martínez-Torres I et al. Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. Parkinsonism Relat Disord, 2019. 68: 40–45. doi: 10.1016/j.parkreldis.2019.09.032.

40. Vintonyak O, Gorges M, Müller HP et al. Patterns of eye movement impairment correlate with regional brain atrophy in neurodegenerative parkinsonism. Neurodegener Dis 2017; 17 (4–5): 117–126. doi: 10.1159/000454880.

41. Panyakaew P, Anan C, Bhidayasiri R. Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. Parkinsonism Relat Disord 2019; 66: 94–99. doi: 10.1016/j.parkreldis.2019.07.016.

42. Ondo W, Warrior D, Overby A et al. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson‘s disease and healthy controls. Arch Neurol 2000; 57 (10): 1464–1469. doi: 10.1001/archneur.57.10.1464.

43. Dale ML, Horak FB, Wright WG et al. Impaired perception of surface tilt in progressive supranuclear palsy. PLoS One 2017; 12 (3): e0173351. doi: 10.1371/journal.pone.0173351.

44. Kammermeier S, Maierbeck K, Dietrich L et al. Qualitative postural control differences in idiopathic Parkinson‘s disease vs. progressive supranuclear palsy with dynamic-on-static platform tilt. Clin Neurophysiol 2018; 129 (6): 1137–1147. doi: 10.1016/j.clinph.2018.03.002.

45. Tykalova T, Rusz J, Klempir J et al. Distinct patterns of imprecise consonant articulation among Parkinson‘s disease, progressive supranuclear palsy and multiple system atrophy. Brain Lang 2017; 165: 1–9. doi: 10.1016/j.bandl.2016.11.005.

46. de Yébenes JG, Sarasa JL, Daniel SE et al. Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. Brain 1995; 118 (Pt 5): 1095–1103. doi: 10.1093/brain/118.5.1095.

47. Ali F, Josephs K. The dia­gnosis of progressive supranuclear palsy: current opinions and challenges. Expert Rev Neurother 2018; 18 (7): 603–616. doi: 10.1080/14737175.2018.1489241.

48. Im SY, Kim YE, Kim YJ. Genetics of progressive supranuclear palsy. J Mov Disord 2015; 8 (3): 122–129. doi: 10.14802/jmd.15033.

49. Ingelsson M, Ramasamy K, Russ C et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol 2007; 114 (5): 471–479. doi: 10.1007/s00401-007-0280-z.

50. Borroni B et al. Genetic bases of progressive supranuclear palsy: the MAPT tau disease. Curr Med Chem 2011; 18 (17): 2655–2660. doi: 10.2174/092986711795933722.

51. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–359. doi: 10.1001/archneur.1964.00460160003001.

52. Kammermeier S, Dietrich L, Maierbeck K et al. Postural stabilization differences in idiopathic parkinson‘s disease and progressive supranuclear palsy during self-triggered fast forward weight lifting. Front Neurol 2017; 8: 743. doi: 10.3389/fneur.2017.00743.

53. Hoglinger GU, Respondek G, Stamelou M et al. Clinical dia­gnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017; 32 (6): 853–864. doi: 10.1002/mds.26987.

54. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002; 1 (6): 359–369. doi: 10.1016/s1474-4422 (02) 00161-8.

55. Cronin T, Arshad Q, Seemungal BM. Vestibular deficits in neurodegenerative disorders: balance, dizziness, and spatial disorientation. Front Neurol 2017; 8: 538. doi: 10.3389/fneur.2017.00538.

56. Fujioka S, Algom AA, Murray ME et al. Tremor in progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 27: 93–97. doi: 10.1016/j.parkreldis.2016.03.015.

57. Anagnostou E, Karavasilis E, Potiri I et al. A cortical substrate for square-wave jerks in progressive supranuclear palsy. J Clin Neurol 2020; 16 (1): 37–45. doi: 10.3988/jcn.2020.16.1.37.

58. Quinn N. The „round the houses“ sign in progressive supranuclear palsy. Ann Neurol 1996; 40 (6): 951. doi: 10.1002/ana.410400630.

59. Matsumoto H, Inaba T, Kakumoto T et al. Progressive supranuclear palsy with wall-eyed bilateral internuclear ophthalmoplegia syndrome: authors‘ second case. Case Rep Neurol 2019; 11 (2): 205–208. doi: 10.1159/000501394.

60. Batla A, Nehru R, Vijay T. Vertical wrinkling of the forehead or Procerus sign in progressive supranuclear palsy. J Neurol Sci 2010; 298 (1–2): 148–149. doi: 10.1016/j.jns.2010.08.010.

61. Marsili L, Bologna M, Kjovic M et al. Dystonia in atypical parkinsonian disorders. Parkinsonism Relat Disord 2019; 66: 25–33. doi: 10.1016/j.parkreldis.2019.07.030.

62. Boxer AL, Lang AE, Grossman M et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014; 13 (7): 676–685. doi: 10.1016/S1474-4422 (14) 70088-2.

63. Kim JH, McCann CM. Communication impairments in people with progressive supranuclear palsy: a tutorial. J Commun Disord 2015; 56: 76–87. doi: 10.1016/j.jcomdis.2015.06.002.

64. Skodda S, Visser W, Schlegel U. Acoustical analysis of speech in progressive supranuclear palsy. J Voice 2011; 25 (6): 725–731. doi: 10.1016/j.jvoice.2010.01.002.

65. Clark HM, Stierwalt JA, Tosakulwong N et al. Dysphagia in progressive supranuclear palsy. Dysphagia 2020; 35 (4): 667–676. doi: 10.1007/s00455-019-10073-2.

66. Iwasaki Y, Yoshida M, Hashizume Y et al. Widespread spinal cord involvement in progressive supranuclear palsy. Neuropathology 2007; 27 (4): 331–340. doi: 10.1111/j.1440-1789.2007.00787.x.

67. Vitaliani R, Scaravilli T, Egarter-Vigl E et al. The pathology of the spinal cord in progressive supranuclear palsy. J Neuropathol Exp Neurol 2002; 61 (3): 268–274. doi: 10.1093/jnen/61.3.268.

68. Gawel M, Jamrozik Z, Szmidt-Salkowska E et al. Electrophysiological features of lower motor neuron involvement in progressive supranuclear palsy. J Neurol Sci 2013; 324 (1–2): 136–139.

69. Nomura T, Inoue Y, Takigawa H et al. Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson‘s disease. Parkinsonism Relat Disord 2012; 18 (4): 394–396. doi: 10.1016/j.parkreldis.2011.10.018.

70. Walsh CM, Ruoff L, Walker K et al. Sleepless night and day, the plight of progressive supranuclear palsy. Sleep 2017; 40 (11), zsx154. doi: 10.1093/sleep/zsx154.

71. Yousaf T, Pagano G, Wilson H et al. Neuroimaging of sleep disturbances in movement disorders. Front Neurol 2018; 9: 767. doi: 10.3389/fneur.2018.00767.

72. Oliveira MC, Ling H, Lees AJ et al. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2019; 90 (5): 555–561. doi: 10.1136/jnnp-2018-319374.

73. Yamamoto T, Tateno F, Sakakibara R et al. Urinary dysfunction in progressive supranuclear palsy compared with other parkinsonian disorders. PLoS One 2016; 11 (2): e0149278. doi: 10.1371/journal.pone.0149278.

74. Kim KJ, Jeong SJ, Kim JM. Neurogenic bladder in progressive supranuclear palsy: a comparison with Parkinson‘s disease and multiple system atrophy. Neurourol Urodyn 2018; 37 (5): 1724–1730. doi: 10.1002/nau.23496.

75. Sulena, Gupta D, Sharma AK et al. Clinical profile of cognitive decline in patients with parkinson‘s disease, progressive supranuclear palsy, and multiple system atrophy. J Neurosci Rural Pract 2017; 8 (4): 562–568. doi: 10.4103/jnrp.jnrp_154_17.

76. Rittman T, Coyle-Gilchrist IT, Rowe JB. Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag 2016; 6 (6): 499–508. doi: 10.2217/nmt-2016-0027.

77. Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord 2014; 29 (5): 684–693. doi: 10.1002/mds.25872.

78. Smith DT, Archibald N. Spatial working memory in progressive supranuclear palsy. Cortex 2020; 122: 115–122. doi: 10.1016/j.cortex.2018.07.004.

79. Santangelo G, Cuoco S, Pellecchia MT et al. Comparative cognitive and neuropsychiatric profiles between Parkinson‘s disease, multiple system atrophy and progressive supranuclear palsy. J Neurol 2018; 265 (11): 2602–2613. doi: 10.1007/s00415-018-9038-x.

80. Sitek EJ, Wieczorek D, Konkel A et al. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson‘s disease. Psychiatr Pol 2017; 51 (4): 647–659. doi: 10.12740/PP/OnlineFirst/62804.

81. Barker MS, Nelson NL, O’Sullivan JD et al. Energization and spoken language production: Evidence from progressive supranuclear palsy. Neuropsychologia 2018; 119: 349–362. doi: 10.1016/j.neuropsychologia.2018.09.004.

82. Robinson GA, Spooner D, Harrison WJ. Frontal dynamic aphasia in progressive supranuclear palsy: Distinguishing between generation and fluent sequencing of novel thoughts. Neuropsychologia 2015; 77: 62–75. doi: 10.1016/j.neuropsychologia.2015.08.001.

83. Sakae N, Josephs KA, Litvan I et al. Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Mov Disord 2019; 34 (11): 1655–1662. doi: 10.1002/mds.27816.

84. Fiorenzato E, Antonini A, Camparini V et al. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson‘s disease. J Neural Transm (Vienna) 2019; 126 (11): 1437–1445. doi: 10.1007/s00702-019-02065-1.

85. Lansdall CJ, Coyle-Gilchrist IT, Simon Jones P et al. Apathy and impulsivity in frontotemporal lobar degeneration syndromes. Brain 2017, 140 (6): 1792–1807. doi: 10.1093/brain/awx101.

86. Schrag A, Sheikh S, Quinn NP et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25 (8): 1077–1081. doi: 10.1002/mds.22794.

87. Belvisi D, Berardelli I, Suppa A et al. Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatr Dis Treat 2018; 14: 2643–2656. doi: 10.2147/NDT.S178263.

88. Litvan I, Agid Y, Calne D et al. Clinical research criteria for the dia­gnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47 (1): 1–9. doi: 10.1212/wnl.47.1.1.

89. Grimm MJ, Respondek G, Stamelou M et al. How to apply the movement disorder society criteria for dia­gnosis of progressive supranuclear palsy. Mov Disord 2019; 34 (8): 1228–1232. doi: 10.1002/mds.27666.

90. Armstrong MJ. Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep 2018; 18 (3): 12. doi: 10.1007/s11910-018-0819-5.

91. Lopez G, Bayulkem K, Hallett M. Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants. Acta Neurol Scand 2016; 134 (4): 242–249. doi: 10.1111/ane.12546.

92. Litvan I, Mangone CA, McKee A et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60 (6): 615–620. doi: 10.1136/jnnp.60.6.615.

93. Arena JE, Weigand SD, Whitwell JL et al. Progressive supranuclear palsy: progression and survival. J Neurol 2016; 263 (2): 380–389. doi: 10.1007/s00415-015-7990-2.

94. Respondek G, Höglinger GU. The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 22 (Suppl 1): S34–36. doi: 10.1016/j.parkreldis.2015.09.041.

95. Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37 (2): 121–130. doi: 10.1136/jnnp.37.2.121.

96. Respondek G, Stamelou M, Kurz C et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14): 1758–1766. doi: 10.1002/mds.26054.

97. Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 2008; 21 (6): 688–692. doi: 10.1097/WCO.0b013e3283168ddd.

98. Dickson DW, Ahmed Z, Algom AA et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23 (4): 394–400. doi: 10.1097/WCO.0b013e32833be924.

99. Santos-Santos MA, Mandelli ML, Binney RJ et al. Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration. JAMA Neurol 2016; 73 (6): 733–742. doi: 10.1001/jamaneurol.2016.0412.

100. Josephs KA, Katsuse O, Beccano-Kelly DA et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 2006; 65 (4): 396–405. doi: 10.1097/01.jnen.0000218446.38158.61.

101. Storey K, Johanidesová S, Matěj R et al. FTLD-TDP and progressive supranuclear palsy in comorbidity-a report of two cases with different clinical presentations. Neurocase 2017; 23 (1): 5–11. doi: 10.1080/13554794.2016.1264058.

102. Kertesz A, Finger R, Murell J et al. Progressive supranuclear palsy in a family with TDP-43 pathology. Neurocase 2015; 21 (2): 178–84. doi: 10.1080/13554794.2013.878729.

103. Menšíková K, Matěj R, Tučková L et al. Progressive supranuclear palsy phenotype mimicking synucleinopathies. J Neurol Sci 2013; 329 (1–2): 34–37.

104. Boxer AL, Yu JT, Golbe LI et al. Advances in progressive supranuclear palsy: new dia­gnostic criteria, bio­markers, and therapeutic approaches. Lancet Neurol 2017; 16 (7): 552–563. doi: 10.1016/S1474-4422 (17) 30157-6.

105. Jabbari E, Holland N, Chelban V et al. Dia­gnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 2020; 77 (3): 377–388. doi: 10.1001/jamaneurol.2019.4347.

106. Nakashima H, Terada S, Ishizu H et al. An autopsied case of dementia with Lewy bodies with supranuclear gaze palsy. Neurol Res 2003; 25 (5): 533–537. doi: 10.1179/016164103101201788.

107. Constantinides VC, Paraskevas GP, Velonakis G et al. Midbrain morphology in idiopathic normal pressure hydrocephalus: a progressive supranuclear palsy mimic. Acta Neurol Scand 2020; 141 (4): 328–334. doi: 10.1111/ane.13205.

108. Lloyd-Smith Sequeira A, Rizzo JR, Rucker JC. Clinical approach to supranuclear brainstem saccadic gaze palsies. Front Neurol 2017; 8: 429. doi: 10.3389/fneur. 2017.00429.

109. Salsano E, Umeh C, Rufa A et al. Vertical supranuclear gaze palsy in Niemann-Pick type C disease. Neurol Sci 2012; 33 (6): 1225–1232. doi: 10.1007/s10072-012-1155-1.

110. Kresojević N, Mandić-Stojmenović G, Dobričić V et al. Very late-onset Niemann-Pick type C disease: example of progressive supranuclear palsy look-alike disorder. Mov Disord Clin Pract 2020; 7 (2): 211–214. doi: 10.1002/mdc3.12892.

111. Nadjar Y, Hütter-Moncada AL, Latour P et al. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis 2018; 13 (1): 175. doi: 10.1186/s13023-018-0913-4.

112. Bremova-Ertl T, Schiffmann R, Patterson MC et al. Oculomotor and vestibular findings in Gaucher disease type 3 and their correlation with neurological findings. Front Neurol 2017; 8: 711. doi: 10.3389/fneur.2017.00711.

113. Modreanu R, Özdemir G, Buhmann C et al. Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing. J Neurol Sci 2018; 388: 139–140. doi: 10.1016/j.jns.2018.03.023.

114. Vasta R, Nicoletti A, Mostile G et al. Side effects induced by the acute levodopa challenge in Parkinson‘s disease and atypical parkinsonisms. PLoS One 2017; 12 (2): e0172145. doi: 10.1371/journal.pone.0172145.

115. Hiller A, Murchison C, Nichols J et al. The effects of amantadine on the progression of progressive supranuclear palsy (psp). [online]. Available from: https: //n.neurology.org/content/90/15_Supplement/P6.068

116. Stamelou M, Hoglinger G. A review of treatment options for progressive supranuclear palsy. CNS Drugs 2016; 30 (7): 629–636. doi: 10.1007/s40263-016-0347-2.

117. Kompoliti K, Goetz CG, Litvan I et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998; 55 (8): 1099–1102. doi: 10.1001/archneur.55.8.1099.

118. Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 1996; 44 (9): 1072–1074. doi: 10.1111/j.1532-5415.1996.tb02940.x.

119. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341 (7): 543–544. doi: 10.1046/j.1468-1331.2002.0354g.x.

120. Zampieri C, Di Fabio­ RP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial. Phys Ther 2008; 88 (12): 1460–1473. doi: 10.2522/ptj. 20070302.

121. Dash SK. Zolpidem in progressive supranuclear palsy. Case Rep Neurol Med 2013; 2013: 250865. doi: 10.1046/j.1468-1331.2002.0354g.x.

122. Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy. Case Rep Med 2014; 2014: 107064. doi: 10.1155/2014/107064.

123. Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study. Parkinsonism Relat Disord 2009; 15 (1): 59–61. doi: 10.1016/j.parkreldis.2008.01.011.

124. Asociace klinických logopedů České republiky. [online]. Dostupné z URL: https: //www.klinickalogopedie.cz/.

125. SKVIMP. Společnost klinické výživy a intenzivní metabolické péče. [online]. Dostupné z URL: http: //www.skvimp.cz/.

126. Intiso D, Bartolo M, Santamato A et al. The role of rehabilitation in patients with progressive supranuclear palsy: a narrative review. PM R 2018, 10 (6): 636–645. doi: 10.1016/j.pmrj.2017.12.011.

127. Slade SC, Finkelstein DI, McGinley JL et al. Exercise and physical activity for people with progressive supranuclear palsy: a systematic review. Clin Rehabil 2020; 34 (1): 23–33. doi: 10.1177/0269215519877235.

128. Tilley E, McLoughlin J, Koblar SA et al. Effectiveness of allied health therapy in the symptomatic management of progressive supranuclear palsy: a systematic review. JBI Database System Rev Implement Rep 2016; 14 (6): 148–95. doi: 10.11124/JBISRIR-2016-2002352.

129. Phokaewvarangkul O, Bhidayasiri R. How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Transl Neurodegener 2019; 8: 20. doi: 10.1186/s40035-019-0160-1.

130. Wiblin L, Lee M, Burn D. Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2017; 34: 7–14.

131. Spolek pro atypické Parkinsonské syndromy. [online]. Dostupné z URL: https: //aps.estranky.cz/.

132. Brown FS, Rowe JB, Passamonti L et al. Falls in progressive supranuclear palsy. Mov Disord Clin Pract2020; 7 (1): 16–24. doi: 10.1016/j.parkreldis.2016.10.013.

133. Apetauerova D, Scala SA, Hamill RW et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 2016; 3 (5): e266. doi: 10.1212/NXI. 0000000000000266.

134. Chen Z, Chen JA, Shatunov A et al. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov Disord 2019; 34 (7): 1049–1059. doi: 10.1002/mds.27702.

135. Boxer AL, Qureshi I, Ahlijanian M et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol 2019; 18 (6): 549–558. doi: 10.1016/S1474-4422 (19) 30139-5.

Štítky
Dětská neurologie Neurochirurgie Neurologie

Článek vyšel v časopise

Česká a slovenská neurologie a neurochirurgie

Číslo 6

2020 Číslo 6

Nejčtenější v tomto čísle
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#